SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (117)2/5/2019 10:43:33 AM
From: scaram(o)uche  Respond to of 136
 
I once predicted that the Fc's would end up being the products. Hasn't panned out (IgG4-RD has kept things rosy), but this is sort of a wrinkle on theme.

Love this project. Complements Genentech's interest in afmd, too.



To: scaram(o)uche who wrote (117)2/5/2019 2:12:50 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 136
 
GNE has its own IL2 candidate, so IL15 may be complementary and make sense to do deal. It may be NKTR killer in surface (and/or in depth),.. it is up to *time* and science to prove one way or another.

Deal is very good for XNCR, nonetheless.
PS: XmAb24306 is not bispecific Abs.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News